HROMADKA, M., V. CERNA, M. PESTA, A. KUCEROVA, Jiří JARKOVSKÝ, D. RAJDL, R. ROKYTA a Z. MOTOVSKA. Prognostic Value of MicroRNAs in Patients after Myocardial Infarction: A Substudy of PRAGUE-18. Disease Markers. London: Hindawi Publishing Corporation, roč. 2019, NOV 3 2019, s. 1-9. ISSN 0278-0240. doi:10.1155/2019/2925019. 2019.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Prognostic Value of MicroRNAs in Patients after Myocardial Infarction: A Substudy of PRAGUE-18
Autoři HROMADKA, M. (203 Česká republika), V. CERNA (203 Česká republika, garant), M. PESTA (203 Česká republika), A. KUCEROVA (203 Česká republika), Jiří JARKOVSKÝ (203 Česká republika, domácí), D. RAJDL (203 Česká republika), R. ROKYTA (203 Česká republika) a Z. MOTOVSKA (203 Česká republika).
Vydání Disease Markers, London, Hindawi Publishing Corporation, 2019, 0278-0240.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30201 Cardiac and Cardiovascular systems
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 2.738
Kód RIV RIV/00216224:14110/19:00112608
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1155/2019/2925019
UT WoS 000498386400001
Klíčová slova anglicky SUDDEN CARDIAC DEATH; CIRCULATING MICRORNAS; NATRIURETIC PEPTIDE; RISK STRATIFICATION; PREDICTORS; PRASUGREL; MORTALITY; OUTCOMES; IMPACT; DAMAGE
Štítky 14119612, podil, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Marie Šípková, DiS., učo 437722. Změněno: 1. 4. 2020 11:09.
Anotace
Background. The evaluation of the long-term risk of major adverse cardiovascular events and cardiac death in patients after acute myocardial infarction (AMI) is an established clinical process. Laboratory markers may significantly help with the risk stratification of these patients. Our objective was to find the relation of selected microRNAs to the standard markers of AMI and determine if these microRNAs can be used to identify patients at increased risk. Methods. Selected microRNAs (miR-1, miR-133a, and miR-499) were measured in a cohort of 122 patients from the PRAGUE-18 study (ticagrelor vs. prasugrel in AMI treated with primary percutaneous coronary intervention (pPCI)). The cohort was split into two subgroups: 116 patients who did not die (survivors) and 6 patients who died (nonsurvivors) during the 365-day period after AMI. Plasma levels of selected circulating miRNAs were then assessed in combination with high-sensitivity cardiac troponin T (hsTnT) and N-terminal probrain natriuretic peptide (NT-proBNP). Results. miR-1, miR-133a, and miR-499 correlated positively with NT-proBNP and hsTnT 24 hours after admission and negatively with left ventricular ejection fraction (LVEF). Both miR-1 and miR-133a positively correlated with hsTnT at admission. Median relative levels of all selected miRNAs were higher in the subgroup of nonsurvivors (N=6) in comparison with survivors (N=116), but the difference did not reach statistical significance. All patients in the nonsurvivor subgroup had miR-499 and NT-proBNP levels above the cut-off values (891.5 ng/L for NT-proBNP and 0.088 for miR-499), whereas in the survivor subgroup, only 28.4% of patients were above the cut-off values (p=0.001). Conclusions. Statistically significant correlation was found between miR-1, miR-133a, and miR-499 and hsTnT, NT-proBNP, and LVEF. In addition, this analysis suggests that plasma levels of circulating miR-499 could contribute to the identification of patients at increased risk of death during the first year after AMI, especially when combined with NT-proBNP levels.
VytisknoutZobrazeno: 18. 4. 2024 09:43